Functionally speaking, the S-binding of the ACE2 catalytic region suppresses ACE2’s role in angiotensin release and disrupts the body’s renin–angiotensin–aldosterone system (RAAS) leading to hypertension, vasoconstriction, inflammation, fibrosis, thrombosis, and pulmonary damage (64–66); these complications are also commonly observed in patients of morbid obesity. Here, ACE2 is linked to hypertensive disorder.